Invokana & Invokamet Studies
Independent studies show the diabetes drug Invokana increases the risk of amputations. Patients with type-II diabetes who take a class of drugs known as sodium–glucose cotransporter 2 (SGLT2) inhibitors will now need to take in consideration great risks related to limb loss after studies showed these medications surprisingly increase the risk of amputation.
FDA Boxed Warning
In May 2017 the FDA issued an official safety announcement about increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
“Based on new data from two large clinical trials, the U.S. Food and Drug Administration (FDA) has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.”
“Drugs to treat diabetes have been undergoing a positive transformation in the last three or four years. It used to be we would test diabetes drugs to see if they lowered glucose levels and did not cause heart problems. Now, we test drugs and expect to see them not only lower glucose but improve cardiovascular health. It’s been extraordinary. But, now we might be finding out that there are glitches along the way.”
One study, "Canagliflozin Cardiovascular Assessment Study or CANVAS" first posted on December 15, 2009, and then updated in July of 2017, stated “The data shows that amputations of the toes and forefoot—and fewer above the ankle—occurred about twice as often in subjects taking Invokana than taking placebo.”
The Endocrine Web Magazine posted an article in May 2017: "The risks were twice as high in those treated with the drug"
Over a year's time, the amputation risks were evaluated to be 7 of every 1,000 treated with 100 milligrams of the drug, versus 3 of every 1,000 on placebo.
“The decision, announced May 16, was not unexpected. It therefore came as no surprise.”
Invokana Amputations Warning
FDA adds “Black Boxed Warning” to Invokana label.
After reviewing data from two large clinical trials, the U.S. Food and Drug Administration (FDA) concluded that the type 2 diabetes medicine canagliflozin, the active ingredient in Invokana, causes an increased risk of leg and foot amputations.
As a result, the FDA is requiring its most stringent warning, the Boxed Warning, be added to Invokana labels regarding the risk of amputation.
Clinical trial results showed that patients treated with Invokana were twice as likely to suffer amputations when compared to nonusers.
Injuries included amputations of the toe and foot, as well as the leg both below and above the knee. As the FDA safety announcement of May 2017 describes, some patients in the study experienced more than one amputation, sometimes affecting both limbs.
“Based on new data from two large clinical trials, the FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.”
Do you qualify to File an Invokana Amputations Lawsuit?
Financial compensation may be available for individuals who have suffered an amputation while taking Invokana or Invokamet.
Patients who were prescribed one of these diabetic medications and suffered a limb amputation may qualify to file an Invokana amputations lawsuit.
If you or your family member has suffered an amputation after a taking Invokana or Invokamet, contact us today. We will connect you with an experienced attorney , who specializes in dealing with such cases. Our experienced Invokana lawyers have the required knowledge to review the facts of your situation to help determine if your diabetic medication could have caused the amputation in your specific case. Our Invokana attorneys provide free consultations.
If your answers meet the requirements for an Invokana lawsuit, you may become eligible to receive a financial settlement to compensate you for your amputation.
What is Invokana?
INVOKANA® (canagliflozin) is a drug used to treat type 2 diabetes, manufactured by Janssen, Pharmaceutical Companies of Johnson & Johnson
Invokana is an oral medication for type 2 diabetes that helps to lower blood glucose levels by encouraging the body to filter out more glucose from the blood and excrete it via the urine.
Invokana is in a class of drugs called sodium-glucose transport protein 2 (or SGLT2) inhibitors. These drugs work by increasing the amount of glucose that gets passed out in the urine. When blood passes through, the kidneys filter glucose out of the blood and the SGLT proteins then help reabsorb glucose back into the blood. SGLT2 proteins are responsible for 90% of the glucose that is reabsorbed, so by blocking the action of these proteins, less glucose is reabsorbed and so more glucose is excreted via the urine.
Invokana was first approved by FDA and released to U.S. market in March 2013
The first FDA revision on Invokana’s label was issued on June 2016, when the FDA strengthened kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet)
In May of 2017 the U.S. Food and Drug Administration (FDA) concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations.
Invokana Lawsuit Commercial
Have you seen a commercial about the Invokana Lawsuit?
You may have seen our Invokana amputations commercial
during one of your favorite nationally televised shows.
“The FDA has recently warned about an increased risk of leg and foot amputations associated with the use of certain diabetic medications such as Invokana and Invokamet. If you or a loved one, took the diabetes medications Invokana or Invokamet, and then suffered an amputation, call the Relion Group now. We are here to help you get the justice you deserve.”
INVOKANA® is a trademark of JOHNSON & JOHNSON
INVOKAMET® is a trademark of JOHNSON & JOHNSON